Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 11/2009

01.11.2009 | Otology

The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus

verfasst von: Abdullah Ayçiçek, Zafer Çetinkaya, Halil Kiyici, Fethullah Kenar, Gülşah Aşik, Nuri Kiraz

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

The purpose of the study was to evaluate the effectiveness of caspofungin and voriconazole in the treatment of experimental Aspergillus otits media in an experimental rabbit model. A total of 30 New Zealand white rabbits were divided into four treatment groups and one control group. The rabbits were immunosuppressed by cyclophosphamide and triamcinolone acetonide. The right ear of each rabbit was infected by an injection of the inoculum of 0.1 ml (8.6 × 103 CFU/0.1 ml) of Aspergillus fumigatus into the middle ear cavity. At 72 h after the inoculation, amphotericin B 1 mg/kg per day (n = 6), itraconazole 10 mg/kg per day (n = 6), voriconazole 10 mg/kg per day (n = 6) and caspofungin 5 mg/kg per day (n = 6) were injected to each treatment group. No antifungal drug was administered to the control group (n = 6). Clinical and histopathological examination scores and microbiological analysis of middle ear mucosa were compared.There was statistically significant difference in the clinical scores, histopathological scores, and mean CFU/g between the treatment and control groups (P < 0.05). There was no statistically significant difference among the treatment groups in the clinical and histopathological scores, whereas there was statistically significant difference in the mean CFU/g (P < 0.05). The mean CFU/g of amphotericin B and caspofungin groups were similar and both were lower than the itraconazole and voriconazole groups. Also, the mean CFU/g of voriconazole group was lower than the itraconazole group (P < 0.05). Caspofungin and voriconazole were demonstrated at least as effective as amphotericin B and itraconazole. We suggest that caspofungin and voriconazole may be considered for the treatment of fungal infection of the ear.
Literatur
1.
Zurück zum Zitat Ohki M, Ito K, Ishimoto S (2001) Fungal mastoiditis in an immunocompetent adult. Eur Arch Otorhinolaryngol 258:106–108PubMedCrossRef Ohki M, Ito K, Ishimoto S (2001) Fungal mastoiditis in an immunocompetent adult. Eur Arch Otorhinolaryngol 258:106–108PubMedCrossRef
2.
Zurück zum Zitat Gussen R, Canalis RF (1982) Mucormycosis of the temporal bone. Ann Otol Rhinol Laryngol 91:27–32PubMed Gussen R, Canalis RF (1982) Mucormycosis of the temporal bone. Ann Otol Rhinol Laryngol 91:27–32PubMed
3.
Zurück zum Zitat Blackledge FA, Newlands SD (2001) Blastomycosis of the petrous apex. Otolaryngol Head Neck Surg 124:347–349PubMedCrossRef Blackledge FA, Newlands SD (2001) Blastomycosis of the petrous apex. Otolaryngol Head Neck Surg 124:347–349PubMedCrossRef
4.
Zurück zum Zitat Bhally HS, Shields C, Lin SY, Merz WG (2004) Otitis caused by Scedosporium apiospermum in an immunocompetent child. Int J Pediatr Otorhinolaryngol 68:975–978PubMedCrossRef Bhally HS, Shields C, Lin SY, Merz WG (2004) Otitis caused by Scedosporium apiospermum in an immunocompetent child. Int J Pediatr Otorhinolaryngol 68:975–978PubMedCrossRef
5.
Zurück zum Zitat Chang CY, Schell WA, Perfect JR, Hulka GF (2005) Novel use of a swimming pool biocide in the treatment of a rare fungal mastoiditis. Laryngoscope 115:1065–1069PubMedCrossRef Chang CY, Schell WA, Perfect JR, Hulka GF (2005) Novel use of a swimming pool biocide in the treatment of a rare fungal mastoiditis. Laryngoscope 115:1065–1069PubMedCrossRef
6.
Zurück zum Zitat Maschmeyer G, Ruhnke M (2004) Update on antifungal treatment of invasive Candida and Aspergillus infections. Mycoses 47:263–276PubMedCrossRef Maschmeyer G, Ruhnke M (2004) Update on antifungal treatment of invasive Candida and Aspergillus infections. Mycoses 47:263–276PubMedCrossRef
7.
Zurück zum Zitat Slack CL, Watson DW, Abzug MJ, Shaw C, Chan KH (1999) Fungal mastoiditis in immunocompromised children. Arch Otolaryngol Head Neck Surg 125:73–75PubMed Slack CL, Watson DW, Abzug MJ, Shaw C, Chan KH (1999) Fungal mastoiditis in immunocompromised children. Arch Otolaryngol Head Neck Surg 125:73–75PubMed
8.
Zurück zum Zitat Patterson TF (2005) Advances and challenges in management of invasive mycoses. Lancet 366:1013–1025PubMedCrossRef Patterson TF (2005) Advances and challenges in management of invasive mycoses. Lancet 366:1013–1025PubMedCrossRef
9.
Zurück zum Zitat Shao PL, Huang LM, Hsueh PR (2007) Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents 30:487–495PubMedCrossRef Shao PL, Huang LM, Hsueh PR (2007) Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents 30:487–495PubMedCrossRef
10.
Zurück zum Zitat Patterson TF, Miniter P, Ryan JL, Andriole VT (1988) Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. J Infect Dis 158:415–422PubMed Patterson TF, Miniter P, Ryan JL, Andriole VT (1988) Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. J Infect Dis 158:415–422PubMed
11.
Zurück zum Zitat Kirkpatrick WR, McAtee RK, Fothergill AW, Loebenberg D, Rinaldi MG, Patterson TF (2000) Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 44:780–782PubMedCrossRef Kirkpatrick WR, McAtee RK, Fothergill AW, Loebenberg D, Rinaldi MG, Patterson TF (2000) Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 44:780–782PubMedCrossRef
12.
Zurück zum Zitat Sandhu P, Xu X, Bondiskey PJ et al (2004) Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 48:1272–1280PubMedCrossRef Sandhu P, Xu X, Bondiskey PJ et al (2004) Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 48:1272–1280PubMedCrossRef
13.
Zurück zum Zitat Kirkpatrick WR, Vallor AC, McAtee RK et al (2005) Combination therapy with terbinafine and amphotericin B in a rabbit model ofexperimental invasive aspergillosis. Antimicrob Agents Chemother 49:4751–4753PubMedCrossRef Kirkpatrick WR, Vallor AC, McAtee RK et al (2005) Combination therapy with terbinafine and amphotericin B in a rabbit model ofexperimental invasive aspergillosis. Antimicrob Agents Chemother 49:4751–4753PubMedCrossRef
14.
Zurück zum Zitat Roffey SJ, Cole S, Comby P et al (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731–741PubMedCrossRef Roffey SJ, Cole S, Comby P et al (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731–741PubMedCrossRef
15.
Zurück zum Zitat Lewis RE, Prince RA, Chi J, Kontoyiannis DP (2002) Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46:3208–3214PubMedCrossRef Lewis RE, Prince RA, Chi J, Kontoyiannis DP (2002) Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46:3208–3214PubMedCrossRef
16.
Zurück zum Zitat Barry B, Muffat-Joly M, Bauchet J et al (1996) Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 40:1977–1982PubMed Barry B, Muffat-Joly M, Bauchet J et al (1996) Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 40:1977–1982PubMed
17.
Zurück zum Zitat National Committee for Clinical Laboratory Standards: reference method for broth dilution antifungal susceptibility testing of yeasts (2002) Approved standard, 2nd edn. NCCLS document M27-A2. Wayne, PA: UCCLS National Committee for Clinical Laboratory Standards: reference method for broth dilution antifungal susceptibility testing of yeasts (2002) Approved standard, 2nd edn. NCCLS document M27-A2. Wayne, PA: UCCLS
18.
Zurück zum Zitat Chirch L, Roche P, Fuhrer J (2008) Successful treatment of invasive Aspergillus sinusitis with caspofungin and voriconazole. Ear Nose Throat J 87:30–33PubMed Chirch L, Roche P, Fuhrer J (2008) Successful treatment of invasive Aspergillus sinusitis with caspofungin and voriconazole. Ear Nose Throat J 87:30–33PubMed
19.
Zurück zum Zitat Amonoo-Kuofi K, Tostevin P, Knight JR (2005) Aspergillus mastoiditis in a patient with systemic lupus erythematosus: a case report. Skull Base 15:109–112PubMedCrossRef Amonoo-Kuofi K, Tostevin P, Knight JR (2005) Aspergillus mastoiditis in a patient with systemic lupus erythematosus: a case report. Skull Base 15:109–112PubMedCrossRef
20.
Zurück zum Zitat Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new “gold standard”. Clin Infect Dis 37:415–425PubMedCrossRef Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new “gold standard”. Clin Infect Dis 37:415–425PubMedCrossRef
21.
Zurück zum Zitat Kartsonis NA, Nielsen J, Douglas CM (2003) Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 6:197–218PubMedCrossRef Kartsonis NA, Nielsen J, Douglas CM (2003) Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 6:197–218PubMedCrossRef
22.
Zurück zum Zitat Maertens J, Raad I, Petrikkos G et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563–1571PubMedCrossRef Maertens J, Raad I, Petrikkos G et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563–1571PubMedCrossRef
23.
Zurück zum Zitat Walsh TJ, Teppler H, Donowitz GR et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402PubMedCrossRef Walsh TJ, Teppler H, Donowitz GR et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402PubMedCrossRef
24.
Zurück zum Zitat Heinz WJ, Einsele H (2008) Caspofungin for treatment of invasive aspergillus infections. Mycoses 51:47–57PubMedCrossRef Heinz WJ, Einsele H (2008) Caspofungin for treatment of invasive aspergillus infections. Mycoses 51:47–57PubMedCrossRef
25.
Zurück zum Zitat Boogaerts M, Winston DJ, Bow EJ et al (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 135:412–422PubMed Boogaerts M, Winston DJ, Bow EJ et al (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 135:412–422PubMed
26.
Zurück zum Zitat Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA (2003) Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41:3623–3626PubMedCrossRef Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA (2003) Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41:3623–3626PubMedCrossRef
27.
Zurück zum Zitat Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMedCrossRef Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMedCrossRef
28.
Zurück zum Zitat Denning DW, Ribaud P, Milpied N et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571PubMedCrossRef Denning DW, Ribaud P, Milpied N et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571PubMedCrossRef
29.
Zurück zum Zitat Troke PF, Schwartz S, Ruhnke M et al. (2003) Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. Abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14–17, M-1755, p 476 Troke PF, Schwartz S, Ruhnke M et al. (2003) Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. Abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14–17, M-1755, p 476
30.
Zurück zum Zitat Serrano Mdel C, Valverde-Conde A, Chávez MM et al (2003) In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 45:131–135PubMedCrossRef Serrano Mdel C, Valverde-Conde A, Chávez MM et al (2003) In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 45:131–135PubMedCrossRef
Metadaten
Titel
The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus
verfasst von
Abdullah Ayçiçek
Zafer Çetinkaya
Halil Kiyici
Fethullah Kenar
Gülşah Aşik
Nuri Kiraz
Publikationsdatum
01.11.2009
Verlag
Springer-Verlag
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 11/2009
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-009-0963-2

Weitere Artikel der Ausgabe 11/2009

European Archives of Oto-Rhino-Laryngology 11/2009 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.